Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years
News provided by
Share this article
Share this article
AUSTIN, Texas, Jan. 31, 2021 /PRNewswire/ Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE clinical trial that demonstrate Edwards bioprosthetic surgical aortic valve with the company s novel RESILIA tissue platform show favorable safety and hemodynamic performance through a median of five years follow-up. The data were presented at the 57th annual meeting of the Society of Thoracic Surgeons. There continues to be a significant focus placed on tissue valve durability given the increase in life expectancy and lifestyle implications for more active patients who historically would receive mechanical valves, said Joseph E. Bavaria, M.D., lead enroller and site principal investigator for the COMMENCE study and the Brooke Roberts-William M. Measey professor of surgery and vice chief of the division of cardio